- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07811583
Establishment of a Perioperative Dynamic Prediction Model for Cardiac Surgery-associated Acute Kidney Injury
9 settembre 2026 aggiornato da: China National Center for Cardiovascular Diseases
Cardiac surgery-associated Acute Kidney Injury (CSA-AKI) is one of the most common complications after cardiovascular Surgery, with an incidence rate as high as 30-50%.
CSA-AKI has many hazards, including significantly increasing the hospital stay of patients after surgery and greatly increasing medical costs.
Moreover, it significantly raises the short-term and long-term mortality (by 3 to 8 times) and the risk of occurrence or aggravation of chronic kidney disease (CKD) in patients after surgery.
These risks increase with the aggravation of CSA-AKI.
Therefore, early prevention and treatment throughout the perioperative period of CSA-AKI is crucial for improving prognosis.
Early prediction, especially preoperative prediction, is the prerequisite for the early prevention and treatment of CSA-AKI throughout the course.
The aim of this study is to establish a dynamic prediction model for the entire perioperative period of CSA-AKI, with the expectation of improving the prediction and diagnosis of CSA-AKI for the development and validation of a prediction model based on a multicenter retrospective cohort.
Using retrospective multimodal data of perioperative cardiovascular surgeries from hospitals such as Beijing, Central China, Yunnan and Fuwai Hospital in Shenzhen, and based on artificial intelligence technologies (such as machine learning), a CSA-AKI risk prediction model suitable for the entire perioperative period dynamics of various surgical types was constructed.
Panoramica dello studio
Stato
Attivo, non reclutante
Condizioni
Tipo di studio
Osservativo
Iscrizione (Stimato)
70000
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
No
Metodo di campionamento
Campione non probabilistico
Popolazione di studio
The cohort included adult patients who underwent cardiovascular surgery from 2015 to 2025 (Beijing) and from 2022 to 2025 (branch hospital).
Descrizione
Inclusion Criteria:
- 1. Age no less than 18 years old;
- 2. Patients who underwent cardiovascular surgeries at Fuwai Hospital in Beijing from 2015 to 2025 and at Fuwai Hospitals in Central China, Yunnan and Shenzhen from 2022 to 2025;
- 3. At least one blood creatinine test should be conducted within 48 hours after the operation, and at least two blood creatinine tests should be conducted within one week after the operation.
Exclusion Criteria:
- 1. Lack of preoperative baseline creatinine;
- 2. Patients who developed AKI before surgery or whose AKI did not recover: The definition of AKI follows the KDIGO 2012 guideline;
- 3. Patients with preoperative creatinine levels exceeding 354umol/L or those in CKD stage 5.
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The occurrence of CSA-AKI
Lasso di tempo: The assessment will be conducted from the end of the surgery until the 7th day after the operation
|
CSA-AKI is defined as: an increase of ≥26.5 µmol/L in serum creatinine (SCr) within 48 hours after cardiovascular surgery compared with the baseline, or an increase of ≥ 50% of the baseline value within 7 days after surgery.
|
The assessment will be conducted from the end of the surgery until the 7th day after the operation
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The occurrence of severe CSA-AKI(i.e. AKI stage 2 or 3)
Lasso di tempo: The assessment will be conducted from the end of the surgery until the 7th day after the operation
|
Acute kidney injury at stage 2 or stage 3 as defined by the KDIGO 2012 guidelines.AKI stage 2 is defined as:meet any of the following conditions:
AKI stage 3 is defined as: meeting any of the following conditions:
|
The assessment will be conducted from the end of the surgery until the 7th day after the operation
|
|
The occurrence of persistent acute kidney injury
Lasso di tempo: 48 hours after the diagnosis of acute kidney injury
|
Persistent acute kidney injury is defined as acute kidney injury that persists for more than 48 hours after its initial diagnosis, based on serum creatinine and/or urine output according to KDIGO criteria.
|
48 hours after the diagnosis of acute kidney injury
|
|
Renal replacement therapy or in-hospital death
Lasso di tempo: From the end of cardiac surgery until the date of first occurrence of renal replacement therapy or in-hospital death, whichever came first, assessed up to 1 year after cardiac surgery.
|
Receiving any form of renal replacement therapy (such as continuous renal replacement therapy, intermittent hemodialysis, etc.) or any in-hospital death caused by any reason.
|
From the end of cardiac surgery until the date of first occurrence of renal replacement therapy or in-hospital death, whichever came first, assessed up to 1 year after cardiac surgery.
|
|
CSA-AKI as defined by the AKIN standard
Lasso di tempo: From the preoperative period to 48 hours after the operation
|
CSA-AKI as defined by AKIN: that is, the increase of serum creatinine within 48 hours is >26.5umol/L or > 50% of the baseline;
|
From the preoperative period to 48 hours after the operation
|
|
New CKD or progression of existing CKD
Lasso di tempo: From the preoperative baseline assessment through 1 year after cardiac surgery
|
Chronic kidney disease (CKD) is defined according to the KDIGO 2024 guidelines.
CKD progression is defined as: an estimated decrease in glomerular filtration rate (eGFR) from baseline of more than 25%, or an average annual eGFR decrease rate of more than 5 ml/min/1.73m²
|
From the preoperative baseline assessment through 1 year after cardiac surgery
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
1 gennaio 2015
Completamento primario (Effettivo)
31 dicembre 2025
Completamento dello studio (Stimato)
31 dicembre 2027
Date di iscrizione allo studio
Primo inviato
3 agosto 2026
Primo inviato che soddisfa i criteri di controllo qualità
9 settembre 2026
Primo Inserito (Effettivo)
10 settembre 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
10 settembre 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
9 settembre 2026
Ultimo verificato
1 dicembre 2025
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2025-GSP-TS-2
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .